Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 02, 2021 08:30 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights
August 16, 2021 08:15 ET
|
Reviva Pharmaceuticals
-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million -Expected to Initiate Pivotal Phase 3 Clinical Trial in Schizophrenia in Q4’21 -$35.8...
Reviva Added to Russell Microcap® Index
June 28, 2021 07:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical...
Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering
May 26, 2021 20:43 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
April 26, 2021 06:00 ET
|
Reviva Pharmaceuticals
Met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective DisorderMet primary endpoint of reduction in Positive and Negative Syndrome Scale...
Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update
March 22, 2021 08:26 ET
|
Reviva Pharmaceuticals
-Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market- -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals...
Reviva Pharmaceuticals Holdings, Inc. to Present at the Maxim Group Inaugural 2021 Emerging Growth Virtual Conference
March 11, 2021 17:36 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical...
Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 04, 2021 17:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva”) today announced that its wholly owned subsidiary...
Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.
December 14, 2020 09:20 ET
|
Reviva Pharmaceuticals
Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW NEW YORK and CUPERTINO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc., a Delaware...
Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Shareholder Meeting Date to Approve the Business Combination
November 18, 2020 08:30 ET
|
Reviva Pharmaceuticals
NEW YORK and CUPERTINO, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ:...